Research shows overall survival benefit for patients with Stage III soft tissue sarcomas

(Fox Chase Cancer Center) Fox Chase Cancer Center researchers have carried out the first retrospective analysis of adjuvant chemotherapy's impact on overall survival in patients with stage III soft tissue sarcomas (STS), adjusted for socioeconomic status and other variables. The findings show that regardless of socioeconomic status and comorbidities, adjuvant chemotherapy improved survival by approximately 23 percent in stage III STS.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news